TPM3 and uterine corpus sarcoma: Their study details distinct morphological and immunohistochemical features differentiating NTRK‐fusion cervical sarcomas from other uterine sarcoma types and underscores the positive response of these tumors to targeted therapies such as the TRK inhibitor larotrectinib.